Use of volatile agents for sedation in the intensive care unit: A national survey in France

• Published in: PloS one Vol. 16; no. 4; p. e0249889
• Main Authors: Blondonnet, Raiko, Quinson, Audrey, Lambert, Céline, Audard, Jules, Godet, Thomas, Zhai, Ruoyang, Pereira, Bruno, Futier, Emmanuel, Bazin, Jean-Etienne, Constantin, Jean-Michel, Jabaudon, Matthieu
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 15.04.2021; Public Library of Science (PLoS)
• Subjects: Abbreviations; Anesthesia; Anesthesiology; Anesthetics; Benzodiazepines; Biology and Life Sciences; Chemical properties; Coronaviruses; COVID-19; Critical care; Data management; Directors; Draft (gas flow); Ecology and Environmental Sciences; Editing; Engineering and Technology; Epidemiology; Equipment and supplies; Funding; Guidelines; Health care facilities; Hypersensitivity; Innovations; Intensive care; Intensive care units; Investigations; Ischemia; Kidneys; Life Sciences; Mechanical ventilation; Medicine; Medicine and Health Sciences; Methodology; Organs; Physiological aspects; Pregnancy; Pretreatment; Reflectors; Research and Analysis Methods; Respiratory distress syndrome; Reviews; Sedatives; Therapeutic applications; Ventilation; Ventilators; Viral diseases; France
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0249889

Current intensive care unit (ICU) sedation guidelines recommend strategies using non-benzodiazepine sedatives. This survey was undertaken to explore inhaled ICU sedation practice in France. In this national survey, medical directors of French adult ICUs were contacted by phone or email between July and August 2019. ICU medical directors were questioned about the characteristics of their department, their knowledge on inhaled sedation, and practical aspects of inhaled sedation use in their department. Among the 374 ICUs contacted, 187 provided responses (50%). Most ICU directors (73%) knew about the use of inhaled ICU sedation and 21% used inhaled sedation in their unit, mostly with the Anaesthetic Conserving Device (AnaConDa, Sedana Medical). Most respondents had used volatile agents for sedation for <5 years (63%) and in <20 patients per year (75%), with their main indications being: failure of intravenous sedation, severe asthma or bronchial obstruction, and acute respiratory distress syndrome. Sevoflurane and isoflurane were mainly used (88% and 20%, respectively). The main reasons for not using inhaled ICU sedation were: "device not available" (40%), "lack of medical interest" (37%), "lack of familiarity or knowledge about the technique" (35%) and "elevated cost" (21%). Most respondents (80%) were overall satisfied with the use of inhaled sedation. Almost 75% stated that inhaled sedation was a seducing alternative to intravenous sedation. This survey highlights the widespread knowledge about inhaled ICU sedation in France but shows its limited use to date. Differences in education and knowledge, as well as the recent and relatively scarce literature on the use of volatile agents in the ICU, might explain the diverse practices that were observed. The low rate of mild adverse effects, as perceived by respondents, and the users' satisfaction, are promising for this potentially important tool for ICU sedation.